CLN Article

Progress made toward reference system for apolipoproteins

iStock-2296760111

A reference measurement procedure (RMP) and immunoassay-based measurement procedures (MPs) have comparable selectivity for apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB), a recent study shows (Clin Chem 2026; doi.org/10.1093/clinchem/hvag063).

The study was part of an International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) effort to develop a novel reference measurement system for seven clinically relevant apolipoproteins, including ApoA-I and ApoB. Plans for the system include a multiplex mass spectrometry-based RMP and commutable secondary reference materials (RMs), the study authors wrote.

The researchers used 30 clinical samples to study agreement between the RMP and eight immunoassay-based MPs. They also investigated the commutability of eight candidate RMs, which consisted of frozen serum pools, and the existing World Health Organization (WHO)-IFCC standards SP1-01 and SP3-08 for the measurement of blood lipids that serve as critical markers for cardiovascular disease risk.

The study found good correlation between the RMP and immunoassay-based MPs for ApoA-I and ApoB. For ApoA-I, the difference in nonselectivity (DIN) was sufficiently small in relation to the desirable or minimum analytical performance specifications (APSs) based on biological variation for all MP comparisons. These findings indicate that despite their different measurement principles, the liquid chromatography-mass spectrometry (LC-MS)–based RMP and the immunoassay-based MPs have a similar selectivity for ApoA-I, the researchers wrote. For ApoB, DINs were larger, but they were still sufficiently small in relation to the minimum APS for six of the eight MP comparisons. In all, seven candidate RMs showed good commutability, while SP1-01 and one candidate RM showed potential noncommutability for one method comparison.  

Although the study shows some level of agreement among most of the MPs for ApoA-I and ApoB with traceability to the current WHO-IFCC standards, significant differences remain among the immunoassay-based MPs currently used in clinical laboratories. The availability of a new reference measurement system with an LC-MS–based RMP and commutable secondary RMs, combined with a system to monitor the correct implementation of traceability, will help improve the situation, the researchers wrote.

The case for diagnostic testing after atypical cfDNA results

Diagnostic testing clarifies atypical cell-free DNA (cfDNA) screening results and detects clinically relevant abnormalities in the fetus and the mother, a new study concludes (Genet Med 2026; doi: 10.1016/j.gim.2026.102713).

The impact of atypical screening findings on pregnancy outcomes has not yet been studied on a large scale. To address this gap, researchers from a single large reference laboratory aimed to determine the diagnostic yield of invasive diagnostic testing after atypical cfDNA screening and to describe the genetic abnormalities underlying atypical cfDNA results.

The researchers matched 10 years of fluorescence in situ hybridization (FISH), karyotype, and chromosomal microarray analysis (CMA) testing performed on prenatal, newborn, and/or maternal samples to previous cfDNA screenings with atypical results, generating 204 index cases.

Of these 204 index cases, 102 had a diagnostic finding. Eighty-seven diagnostic findings were related to the atypical cfDNA screen. Fifty-five abnormal results were pathogenic, 18 were variants of uncertain significance, and eight were likely benign. Copy number variation (CNV) was the most common finding, occurring in 38 cases, followed by aneuploidy in 37 cases, and chromosome arrangements in 20. The researchers detected uniparental disomy (UPD) in five cases and suspected consanguinity in three. These two smallest categories may be underrepresented because UPD and consanguinity cannot be detected by chromosome analysis or FISH, the researchers noted.

In 99 of the 204 index cases, an atypical cfDNA report was available to review, and in 96 of the cases, information was provided regarding the atypical finding on the test requisition form or through calls to the healthcare provider. Details in the cfDNA report that indicate the chromosome involved, the origin of the finding, and the type of abnormality detected can inform follow-up testing. For example, cfDNA results that appear to be a CNV rather than whole-chromosome aneuploidy should prioritize CMA over chromosome analysis, the study authors wrote.

The researchers urged cfDNA laboratories to provide details on the suspected abnormality origin and type because this information guides downstream testing.  

Pooled testing may expand access to molecular testing for TB

Pooled sputum testing halves the number of cartridges needed to make tuberculosis (TB) diagnoses, according to recent research. This finding suggests that pooled testing could expand access to World Health Organization (WHO)-recommended rapid molecular TB tests using existing laboratory capacity (Lancet Glob Health 2026; doi: 10.1016/j.langlo.2026.104051).

In 2024, only 54% of people diagnosed with TB received a recommended rapid molecular diagnostic test, according to WHO. To explore a potential strategy for narrowing this gap, the researchers evaluated the performance of pooled TB testing in a prospective, observational, multicenter diagnostic accuracy study.

They enrolled individuals with presumptive TB through facility-based case finding in district hospitals and primary health centers in Bangladesh, Brazil, Cameroon, Kenya, Malawi, Nigeria, and Vietnam. The researchers tested sputum individually on Xpert MTB/RIF Ultra (Xpert Ultra) and in pools of two, three, or four specimens on Xpert Ultra. Culture was the microbiological reference standard. The researchers estimated the sensitivity and specificity of pooled testing versus culture, positive percent agreement (PPA) versus individual Xpert Ultra, and cartridge savings. Results were available for 95.2% of participants from 3,666 pools, including 3,195 pools of four.  

Using culture as the reference standard, sensitivity of pooled testing versus individual Xpert Ultra was 84.9% versus 88%, and specificity was 98.3% versus 97.7%. PPA was 90.1%, and it remained above 96% for high, medium, and low individual Xpert Ultra semiquantitative grades, but lower for very low and trace grades.

Pooled testing used 7,028 cartridges versus 14,362 for individual testing, a 51.1% reduction.

Scaling up of this approach could facilitate expanded access to molecular testing in low to moderate tuberculosis positivity settings without the need for additional infrastructure, the researchers wrote.

They added that their study is the first to estimate the diagnostic accuracy of sputum pooling for tuberculosis against culture as a microbiological reference standard, rather than measuring agreement with individual Xpert alone. 

Read the full November-December issue of CLN.

Advertisement

Advertisement